What is REPL's health score?

Replimune Group, Inc. (REPL) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is REPL's estimated fair value?

Based on our 5-year discounted cash flow model, Replimune Group, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is REPL undervalued or overvalued?

Our model currently rates REPL as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

Replimune Group, Inc. (REPL)

Healthcare Inconclusive inconclusive weak

$9.94

Updated: 2026-07-14

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

30 Weak

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk Management

65 Healthy

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Industry Related Stocks

Acumen Pharmaceuticals, Inc. (ABOS) Abpro Holdings, Inc. (ABPO) Abpro Holdings, Inc. (ABPWW) Arcellx, Inc. (ACLX) Alpha Cognition Inc. (ACOG) ADMA BIOLOGICS, INC. (ADMA)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.